or Try an Advanced Search...

    Treatment Of Heart Failure Stocks List

    Symbol Grade Name % Change
    CYTK D Cytokinetics, Incorporated -1.36
    SVRA F Savara, Inc. 3.83
    BCDA F BioCardia, Inc. 2.01
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Heart Failure Clinical Development Heart Disease Aging Associated Diseases Amyotrophic Lateral Sclerosis Biology Biopharmaceutical Biotechnology Bone Bone Marrow Cardiovascular Disease Catheter Cell Therapy Cystic Fibrosis Cytokine Disease Drug Design Dysfunction Ischemia Life Sciences

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Heart Failure stocks.

    Symbol Grade Name Weight
    HRTS D Tema Cardiovascular and Metabolic ETF 3.47
    XBI D SPDR S&P Biotech ETF 1.87
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 1.46
    LABU F Direxion Daily S&P Biotech Bull 3X Shares 1.22
    FMED D Fidelity Disruptive Medicine ETF 1.19
    View all Treatment Of Heart Failure ETFs...
    Compare ETFs
    Compare HRTS to LABU Compare LABU to FMED Compare XBI to LABU

        Treatment Of Heart Failure Stocks Recent News

        Date Stock Title
        Nov 20 CYTK Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
        Nov 19 CYTK Cytokinetics and Bayer partner to develop for aficamten in Japan
        Nov 19 CYTK Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
        Nov 19 CYTK Cytokinetics and Bayer Partner to Expand Aficamten's Reach in Japan
        Nov 19 CYTK Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan
        Nov 19 CYTK Bayer acquires rights to Cytokinetics' heart drug in Japan
        Nov 19 CYTK Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
        Nov 16 CYTK Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
        Nov 16 CYTK Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
        Nov 16 BCDA BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)
        Related Industries: Biotechnology
        Related Stock Lists: Heart Failure Clinical Development Heart Disease Aging Associated Diseases Amyotrophic Lateral Sclerosis Biology Biopharmaceutical Biotechnology Bone Bone Marrow Cardiovascular Disease Catheter Cell Therapy Cystic Fibrosis Cytokine Disease Drug Design Dysfunction Ischemia Life Sciences
        Treatment Of Heart Failure

        Treatment of heart failure depends on the severity of the condition and the underlying cause. Treatment may include lifestyle changes, medications, and medical procedures. Lifestyle changes may include quitting smoking, eating a healthy diet, exercising regularly, and reducing stress. Medications may include diuretics, ACE inhibitors, beta blockers, and other drugs. Medical procedures may include angioplasty, coronary artery bypass grafting, and implantable cardioverter-defibrillators.

        Browse All Tags